Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia

Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia

Background Respiratory syncytial virus (RSV) can cause acute respiratory infection (ARI) and severe symptoms in adults ≥60 years. The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) offers protection to adults against RSV ARI and RSV lower respiratory tract disease (LRTD). We modele...

Full description

Saved in:
Bibliographic Details
Main Authors: Ru Han, Jorge A. Gomez, Chau Ngo Quy, Otavio Cintra, Desiree van Oorschot, Adriana Guzman-Holst
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Expert Review of Vaccines
Subjects:
Adjuvanted RSVPreF3
India
Markov model
public health impact
RSV
Southeast Asia
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2025.2523602
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items